Payment overview · 2025
General Payments
$619.79
31 reported records · 14 companies
Healthcare provider profile · identity verified
Benjamin Wilson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NEVADA, MO · NPI 1417247644
Verified facts
What the public records show
CMS Open Payments records show Benjamin Wilson, M.D. received $619.79 in general payments during 2025 across 31 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rexulti, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $163.63 | 26.4% | 8 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $81.48 | 13.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $68.48 | 11.1% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $49.57 | 8.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.75 | 6.7% | 2 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $39.46 | 6.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.62 | 4.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.43 | 4.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.87 | 3.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.28 | 3.4% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$19.71 | 3.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.15 | 3.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $17.20 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.16 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $619.79 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $163.63 | 8 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $81.48 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $53.78 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $49.57 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.75 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.75 | 2 | 2025 |
Source payment records
|
|||||
| Iovera Normalized: iovera |
Device | Pacira Pharmaceuticals Incorporated | $39.46 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.62 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.43 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 22 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 473 | 93 |
| Lisinopril | Lisinopril | 427 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 409 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 366 | 67 |
| Omeprazole | Omeprazole | 322 | 59 |
| Gabapentin | Gabapentin | 319 | 63 |
| Tramadol Hcl | Tramadol Hcl | 315 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 279 | 58 |
| Losartan Potassium | Losartan Potassium | 217 | 58 |
| Clonazepam | Clonazepam | 209 | 27 |
| Furosemide | Furosemide | 177 | 34 |
| Metformin Hcl | Metformin Hcl | 177 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 165 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 30 |
| Montelukast Sodium | Montelukast Sodium | 154 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 137 | 25 |
| Trazodone Hcl | Trazodone Hcl | 136 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 34 |
| Meloxicam | Meloxicam | 130 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 130 | 33 |
| Alprazolam | Alprazolam | 126 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 105 | suppressed |
| Famotidine | Famotidine | 103 | 17 |
| Diazepam | Diazepam | 99 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 98 | 32 |
| Divalproex Sodium | Divalproex Sodium | 98 | suppressed |
| Simvastatin | Simvastatin | 94 | 21 |
| Celecoxib | Celecoxib | 92 | 14 |
| Topiramate | Topiramate | 85 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | 15 |
| Potassium Chloride | Potassium Chloride | 84 | 22 |
| Olanzapine | Olanzapine | 81 | 12 |
| Allopurinol | Allopurinol | 77 | 14 |
| Risperidone | Risperidone | 77 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 76 | 17 |
| Pregabalin | Pregabalin | 73 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 71 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 15 |
| Carvedilol | Carvedilol | 70 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 13 |
| Ozempic | Semaglutide | 70 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 11 |
| Propranolol Hcl | Propranolol Hcl | 64 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 59 | 17 |
| Eliquis | Apixaban | 58 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 57 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 56 | suppressed |
| Mirtazapine | Mirtazapine | 54 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 14 |
| Sertraline Hcl | Sertraline Hcl | 53 | 11 |
| Linzess | Linaclotide | 52 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Atenolol | Atenolol | 50 | suppressed |
| Baclofen | Baclofen | 48 | suppressed |
| Lorazepam | Lorazepam | 48 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 13 |
| Temazepam | Temazepam | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Ibuprofen | Ibuprofen | 43 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | 13 |
| Carbamazepine | Carbamazepine | 42 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 42 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Phenobarbital | Phenobarbital | 34 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 20 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Buprenorphine | Buprenorphine | 28 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 26 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 26 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Scopolamine | Scopolamine | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 20 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Azithromycin | Azithromycin | 18 | 12 |
| Cephalexin | Cephalexin | 18 | 17 |
| Glipizide | Glipizide | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Enulose | Lactulose | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 16 | suppressed |
| Felbamate | Felbamate | 16 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Cetirizine Hcl | Cetirizine Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Dutasteride | Dutasteride | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | 12 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $619.79 · 31 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Auvelity, CAPLYTA, FANAPT, Iovera, JOURNAVX, Kerendia, MOUNJARO, Ozempic, QULIPTA, REPATHA, REXULTI, UBRELVY, VALTOCO, VRAYLAR, Veozah, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error